Scholar Rock (SRRK) Expected to Announce Quarterly Earnings on Tuesday

Scholar Rock (NASDAQ:SRRK) is anticipated to announce its Q3 2026 results before the market opens on Tuesday, November 10th. Analysts expect the company to announce earnings of ($0.8472) per share and revenue of $0.30 million for the quarter. Parties may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Tuesday, November 10, 2026 at 8:00 AM ET.

Scholar Rock (NASDAQ:SRRK) last released its earnings results on Thursday, August 6th. The company reported ($0.84) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.84). During the same period in the prior year, the firm posted ($0.98) EPS. On average, analysts expect Scholar Rock to post ($3.29) EPS for the current fiscal year and ($2.78) EPS for the next fiscal year.

Scholar Rock Stock Up 2.1%

Shares of SRRK traded up $0.89 during midday trading on Tuesday, hitting $43.80. The stock had a trading volume of 178,647 shares, compared to its average volume of 1,448,875. The firm has a market cap of $5.33 billion, a price-to-earnings ratio of -12.68 and a beta of 0.61. The company has a 50 day simple moving average of $48.20 and a two-hundred day simple moving average of $48.18. The company has a debt-to-equity ratio of 0.77, a current ratio of 7.02 and a quick ratio of 7.02. Scholar Rock has a twelve month low of $27.07 and a twelve month high of $61.76.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on SRRK. JPMorgan Chase & Co. boosted their price objective on shares of Scholar Rock from $63.00 to $70.00 and gave the stock an “overweight” rating in a research report on Monday, September 21st. Truist Financial increased their target price on shares of Scholar Rock from $76.00 to $77.00 and gave the stock a “buy” rating in a report on Thursday, September 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $70.00 target price on shares of Scholar Rock in a research report on Monday, September 21st. TD Cowen reiterated a “buy” rating on shares of Scholar Rock in a research note on Monday, September 14th. Finally, Wedbush reissued an “outperform” rating and set a $64.00 price target on shares of Scholar Rock in a research report on Tuesday, September 15th. Four equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $67.67.

Insider Buying and Selling

In related news, Director Srinivas Akkaraju bought 146,970 shares of Scholar Rock stock in a transaction that occurred on Monday, October 26th. The stock was acquired at an average price of $41.59 per share, with a total value of $6,112,482.30. Following the acquisition, the director owned 6,380,517 shares of the company’s stock, valued at approximately $265,365,702.03. This represents a 2.36% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.30% of the stock is currently owned by company insiders.

About Scholar Rock

Scholar Rock, Inc is a biotechnology company focused on developing medicines that selectively target growth factors in the transforming growth factor beta (TGF-β) superfamily. The company’s research is intended to address serious diseases in which these signaling pathways play an important role, including neuromuscular and metabolic conditions.

Scholar Rock’s lead investigational product is apitegromab, a monoclonal antibody designed to inhibit the activation of myostatin, a protein that limits muscle growth.